Captrust Financial Advisors Makes New Investment in Biohaven Ltd. (NYSE:BHVN)

Captrust Financial Advisors bought a new stake in shares of Biohaven Ltd. (NYSE:BHVN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,862 shares of the company’s stock, valued at approximately $293,000.

Other large investors also recently modified their holdings of the company. nVerses Capital LLC bought a new stake in Biohaven during the third quarter worth about $50,000. Redwood Wealth Management Group LLC bought a new stake in shares of Biohaven during the 2nd quarter worth approximately $61,000. Values First Advisors Inc. acquired a new stake in shares of Biohaven during the 3rd quarter worth approximately $78,000. US Bancorp DE increased its stake in Biohaven by 57.1% in the third quarter. US Bancorp DE now owns 2,173 shares of the company’s stock valued at $109,000 after acquiring an additional 790 shares during the last quarter. Finally, KBC Group NV raised its position in Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock valued at $112,000 after purchasing an additional 443 shares in the last quarter. 88.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BHVN has been the topic of a number of research analyst reports. William Blair raised Biohaven to a “strong-buy” rating in a report on Friday, August 30th. Bank of America lifted their target price on Biohaven from $52.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. TD Cowen increased their target price on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Jefferies Financial Group assumed coverage on shares of Biohaven in a report on Monday, September 16th. They set a “buy” rating and a $57.00 price target on the stock. Finally, Piper Sandler upped their price objective on shares of Biohaven from $66.00 to $76.00 and gave the stock an “overweight” rating in a research report on Monday, September 23rd. Thirteen equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $63.00.

Insider Activity at Biohaven

In other Biohaven news, Director John W. Childs acquired 21,052 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average cost of $47.50 per share, with a total value of $999,970.00. Following the purchase, the director now directly owns 21,052 shares of the company’s stock, valued at $999,970. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gregory Bailey bought 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 24th. The shares were acquired at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the transaction, the director now owns 1,620,071 shares in the company, valued at $71,590,937.49. This represents a 0.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 16.00% of the stock is currently owned by company insiders.

Biohaven Stock Performance

BHVN stock opened at $38.47 on Friday. The company has a market capitalization of $3.89 billion, a P/E ratio of -4.11 and a beta of 1.24. The company has a fifty day moving average price of $48.70 and a 200-day moving average price of $41.77. Biohaven Ltd. has a 52-week low of $26.80 and a 52-week high of $62.21.

Biohaven (NYSE:BHVN) last announced its earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.03). As a group, sell-side analysts forecast that Biohaven Ltd. will post -8.85 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.